Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. The introduction of a new class of disease-modifying anti-rheumatic drugs, which work by inhibiting the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway, has led to new possibilities for achieving remi...

Full description

Saved in:

Bibliographic Details
Published in:	Ugeskrift for læger Vol. 179; no. 44
Main Authors:	Frøling, Malte, Mikkelsen, Clara, Eggertsen, Peter Preben, Stern, Mette, van de Looij, Anne, Deleuran, Bent
Format:	Journal Article
Language:	Danish
Published:	Denmark 30-10-2017
Subjects:	Antirheumatic Agents - adverse effects Antirheumatic Agents - pharmacokinetics Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - physiopathology Azetidines - adverse effects Azetidines - pharmacokinetics Azetidines - therapeutic use Herpes Zoster - chemically induced Humans Janus Kinase Inhibitors - adverse effects Janus Kinase Inhibitors - pharmacokinetics Janus Kinase Inhibitors - therapeutic use Piperidines - adverse effects Piperidines - pharmacokinetics Piperidines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacokinetics Protein Kinase Inhibitors - therapeutic use Pyrimidines - adverse effects Pyrimidines - pharmacokinetics Pyrimidines - therapeutic use Pyrroles - adverse effects Pyrroles - pharmacokinetics Pyrroles - therapeutic use Sulfonamides - adverse effects Sulfonamides - pharmacokinetics Sulfonamides - therapeutic use
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Rheumatoid arthritis (RA) is a chronic inflammatory joint disease. The introduction of a new class of disease-modifying anti-rheumatic drugs, which work by inhibiting the Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway, has led to new possibilities for achieving remission of RA. Tofacitinib and baricitinib are both JAK/STAT inhibitors, which have shown efficacy in line with anti-tumour necrosis factor treatment. The side effects seem manageable, and up to now only increased risk of herpes zoster has raised consideration. JAK/STAT inhibitors create new possibilities for reaching low disease activity or remission for patients with RA.
ISSN:	1603-6824